Abstract
Protein kinase C theta (PKC-) is a key kinase in mediating T cell receptor (TCR) signals. PKC- activated by T cell receptor (TCR) engagement translocates to immunological synapses and regulates the activation of transcriptional factors NF-κB, AP-1, and NFAT. These transcription factors then activate target genes such as IL-2. T cells deficient in PKC- display defects in T cell activation, survival, activation-induced cell death, and the differentiation into inflammatory T cells, both in vitro and in vivo. Since these effector T helper cells are responsible for mediating autoimmunity, selective inhibition of PKC- is considered a treatment for prevention of autoimmune diseases and allograft rejection.
Keywords: PKC-, T cells, TCR signaling, autoimmunity, transplantation rejection, T cell receptor, TCR, antigen presenting cells, APC, histocompatibility complex, MHC, protein tyrosine kinase, diacylglycerol, DAG, central SMAC, peripheral SMAC, distal SMAC, Activationinduced cell death, airway hyperresponsiveness, myelin oligodendrocyte glycoprotein, MOG, experimental autoimmune encephalitis, EAE, collagen-induced arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Volume: 10 Issue: 4
Author(s): Myung-Ja Kwon, Ruiqing Wang, Jian Ma and Zuoming Sun
Affiliation:
Keywords: PKC-, T cells, TCR signaling, autoimmunity, transplantation rejection, T cell receptor, TCR, antigen presenting cells, APC, histocompatibility complex, MHC, protein tyrosine kinase, diacylglycerol, DAG, central SMAC, peripheral SMAC, distal SMAC, Activationinduced cell death, airway hyperresponsiveness, myelin oligodendrocyte glycoprotein, MOG, experimental autoimmune encephalitis, EAE, collagen-induced arthritis
Abstract: Protein kinase C theta (PKC-) is a key kinase in mediating T cell receptor (TCR) signals. PKC- activated by T cell receptor (TCR) engagement translocates to immunological synapses and regulates the activation of transcriptional factors NF-κB, AP-1, and NFAT. These transcription factors then activate target genes such as IL-2. T cells deficient in PKC- display defects in T cell activation, survival, activation-induced cell death, and the differentiation into inflammatory T cells, both in vitro and in vivo. Since these effector T helper cells are responsible for mediating autoimmunity, selective inhibition of PKC- is considered a treatment for prevention of autoimmune diseases and allograft rejection.
Export Options
About this article
Cite this article as:
Kwon Myung-Ja, Wang Ruiqing, Ma Jian and Sun Zuoming, PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/1871530311006040367
DOI https://dx.doi.org/10.2174/1871530311006040367 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of B-Cell Activation by Complement Receptors CD21 and CD35
Current Pharmaceutical Design Systemic Lupus Erythematosus and Other Autoimmune Diseases from Endogenous and Exogenous Agents: Unifying Theme of Oxidative Stress
Mini-Reviews in Medicinal Chemistry The Role of HLA Promoters in Autoimmunity
Current Pharmaceutical Design Defining Peptide Sequences: From Antigenicity to Immunogenicity Through Redundancy
Current Pharmacogenomics Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Mini-Reviews in Medicinal Chemistry Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Potential of Glycolipid Ligands for Natural Killer (NK) T Cells in the Suppression of Autoimmune Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery
Protein & Peptide Letters Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases
Central Nervous System Agents in Medicinal Chemistry Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Deciphering the Antibodyome - Peptide Arrays for Serum Antibody Biomarker Diagnostics
Current Proteomics Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Diabetes Mellitus: A Potential Target for Stem Cell Therapy
Current Stem Cell Research & Therapy Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments
Current Medicinal Chemistry Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design Interactions of Sex Steroids with Mechanisms of Inflammation
Current Drug Targets - Inflammation & Allergy Vasculitis Following Influenza Vaccination: A Review of the Literature
Current Rheumatology Reviews Neuropeptide Receptors in Intestinal Disease: Physiology and Therapeutic Potential
Current Pharmaceutical Design